Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 12, 2020
Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers Etienne Jornod to step down as Executive Chairman. Jacques...
-
Mar 3, 2020
St Gallen, 3 March 2020 - Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This...
-
Feb 20, 2020
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China Gives Vifor Pharma access to largest iron...
-
Feb 17, 2020
St Gallen, 17 February 2020 – Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to...
-
Nov 26, 2019
For a fifth consecutive year, Iron Deficiency Day aims to inform about the impact and symptoms of iron deficiency Iron Deficiency Day 2019 encourages people to ‘take iron seriously’ Supported...
-
Nov 26, 2019
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity...
-
Nov 18, 2019
St Gallen, 18 November 2019 – Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020. Lee Heeson...
-
Sep 11, 2019
St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...
-
Sep 9, 2019
St Gallen, 9 September 2019 – Vifor Pharma announced today that Standard & Poor's (S&P) assigned a BBBcredit rating with stable outlook to Vifor Pharma. This inaugural investment grade credit...
-
Sep 4, 2019
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc....